Elpiscience Biopharma Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2017-09-30
- Employees
- 51
- Market Cap
- -
- Website
- https://www.elpiscience.com
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Registration Number
- NCT05381935
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Part 1 ES002023Drug: Part 2 ES002023
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05075564
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸NEXT Virginia, Fairfax, Virginia, United States
🇺🇸NEXT Austin, Austin, Texas, United States
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Target Recruit Count
- 82
- Registration Number
- NCT04991506
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors
Phase 1
Withdrawn
- Conditions
- Non-small Cell Lung CancerSmall Cell Lung CancerThoracic Tumors
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Registration Number
- NCT04841538
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04730843
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT04009460
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath